The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVRP.L Share News (VRP)

  • There is currently no data for VRP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AZ Electronic Materials directors try to minimize damage

Wed, 10th Apr 2013 16:27

John Whybrow, the Chairman of AZ Electronic Materials, which on Tuesday tanked after it issued a warning on full year revenue, has shown his faith in the chemicals company by enlarging his shareholding. Whybrow acquired 40,000 shares at 254p each for a total trade value of £101,600, taking his stake in the company to 118,541 shares. Geoff Wild, the group's Chief Executive Officer, also made a significant purchase, buying 40,000 shares at 268p each. The £107,200 purchase takes his holding to 885,749.A number of other directors also gave the group their backing with purchases of various sizes. The company reported a 2.0% year-on-year decline in revenue to $19.9m for the three months to April 8th, following lower-than-expected sales in its IC Materials division. The company blamed weak performance and an unfavourable product mix in IC Materials, which includes products for use in integrated circuits and devices. Revenue in the division fell 7.0% year-on-year to $123.3m. As a result, the group's EBITDA (earnings before interest, tax, depreciation and amortisation) margin for the three month period was lower than normal, and will be for the year as a whole, it warned. Group revenue for the full year will be around the same levels as last year, the company added. Having lost around 30% of its value on Tuesday, the stock regained 15% the following morning, boosted in part by a rating upgrade from broker UBS. Top Director BuysCentamin (DI) (CEY) Director name: Mr Josef El-RaghyAmount purchased: 500,000 @ 47.80p Value: £239,000AZ Electronic Materials SA (DI) (AZEM) Director name: Mr Geoff WildAmount purchased: 40,000 @ 268.00p Value: £107,200AZ Electronic Materials SA (DI) (AZEM) Director name: Mr John WhybrowAmount purchased: 40,000 @ 254.00p Value: £101,600Synety Group (SNTY) Director name: Mr Simon CleaverAmount purchased: 40,000 @ 125.00p Value: £50,000AZ Electronic Materials SA (DI) (AZEM) Director name: Mr Andrew AllnerAmount purchased: 10,000 @ 255.00p Value: £25,500Verona Pharma (VRP) Director name: Mr Stuart BottomlyAmount purchased: 1,000,000 @ 2.35p Value: £23,500Mission Marketing Group (TMMG) Director name: Mr Chris GoodwinAmount purchased: 60,000 @ 34.00p Value: £20,400Cenkos Securities (CNKS) Director name: Mr Anthony HotsonAmount purchased: 20,000 @ 87.80p Value: £17,560Port Erin Biopharma Investments Ltd (PEBI) Director name: Mr James (Jim) MellonAmount purchased: 200,000 @ 7.50p Value: £15,000Synety Group (SNTY) Director name: Mr Simon CleaverAmount purchased: 10,000 @ 124.80p Value: £12,480Top Director SellsTelecity Group (TCY) Director name: Mr Brian McArthur MuscroftAmount sold: 98,789 @ 888.00p Value: £877,246Close Brothers Group (CBG) Director name: Mr Stephen R HodgesAmount sold: 76,383 @ 1,016.48p Value: £776,418Berendsen (BRSN) Director name: Mr Peter VentressAmount sold: 61,310 @ 782.80p Value: £479,935Spirax-Sarco Engineering (SPX) Director name: Mr Mark E. VernonAmount sold: 18,362 @ 2,608.78p Value: £479,024Amlin (AML) Director name: Mr Richard A HextallAmount sold: 72,533 @ 423.49p Value: £307,170Tarsus Group (TRS) Director name: Mr Douglas EmslieAmount sold: 86,449 @ 230.00p Value: £198,833National Express Group (NEX) Director name: Mr Dean K FinchAmount sold: 69,571 @ 195.89p Value: £136,283Tarsus Group (TRS) Director name: Mr Neville BuchAmount sold: 43,225 @ 230.00p Value: £99,418Tarsus Group (TRS) Director name: Mr Roger PellowAmount sold: 23,084 @ 230.00p Value: £53,093NR
More News
2 Mar 2018 15:01

BUZZ-Verona Pharma: Soars on positive data from mid-stage study

** British drug developer's U.S.-listed shares up 16 pct at $16.44 in morning trade - second highest gainer amongst Nasdaq-listed companies ** data a

Read more
18 Jan 2017 10:13

Verona Pharma Proposes Share Consolidation Amid Plans To List In US (ALLISS)

Read more
26 Sep 2016 09:39

Verona Pharma appoints sector veteran Morgan as CFO

(ShareCast News) - AIM listed drug development company Verona Pharma appointed sector veteran Piers John Morgan as chief financial officer on Monday, as the company prepares for clinical trials for its flagship drug. Chartered accountant Morgan has 25 years' financial experience and was previously c

Read more
13 Sep 2016 12:04

Verona Pharma makes progress on new respiratory drug

(ShareCast News) - Verona Pharma, a UK based drug development company focused on first-in-class medicines to treat respiratory diseases, reported positive results on new drug "RPL554". The company's lead drug, RPL554, is a first-in-class drug currently in Phase 2 trials as a nebulized maintenance tr

Read more
20 Jun 2016 15:02

UK Shareholder Meetings Calendar - Next 7 Days

Read more
20 Jun 2016 12:50

Verona Pharma secures funding for drug trial

(ShareCast News) - Shares in AIM-listed Verona Pharma rallied on Monday as the drug development company it had successfully secured funding commitments to raise gross proceeds of around £44.7m through a conditional placing that was significantly oversubscribed. Net proceeds from the placing with new

Read more
20 Jun 2016 11:06

LONDON MARKET MIDDAY: Receding Brexit Fear Lifts Stocks And Pound

Read more
20 Jun 2016 09:40

WINNERS & LOSERS SUMMARY: Cat Allergy Disappointment Sinks Circassia

Read more
17 Jun 2016 16:09

Verona Pharma To Raise GBP44.7 Million In Share Placing (ALLIS)

Read more
3 Jun 2016 12:52

Verona Pharma's shares fall as higher R&D costs widen FY loss

(ShareCast News) - Shares in Verona Pharma sagged more than 8% as it turned in a wider full-year pre-tax loss of £8.9m, from a loss of £3.8m, thanks to higher research and development more than doubling. Chief executive Jan-Anders Karlsson said Verona had made substantial clinical progress with its

Read more
3 Jun 2016 06:59

Verona Pharma Loss Widens On Higher Research And Development Costs

Read more
10 May 2016 08:11

Verona Pharma Gets Positive Results From COPD Treatment Study

Read more
15 Mar 2016 10:35

Verona Pharma excites with asthma trial results

(ShareCast News) - Verona Pharma has published further encouraging clinical results for its RPL554 drug to treat chronic obstructive pulmonary disorder (COPD). Tests among asthma patients found the inhaled drug, which has both bronchodilator and anti-inflammatory properties in the same active molecu

Read more
21 Jan 2016 13:31

DIRECTOR DEALINGS: Verona Pharma Chairman Ups Interest

Read more
11 Jan 2016 08:45

Verona Pharma Chief Financial Officer Biresh Roy Leaving Company

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.